U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H12N5O4.Na
Molecular Weight 277.2124
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GANCICLOVIR SODIUM

SMILES

[Na+].NC1=NC2=C(N=CN2COC(CO)CO)C(=O)[N-]1

InChI

InChIKey=JJICLMJFIKGAAU-UHFFFAOYSA-M
InChI=1S/C9H13N5O4.Na/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16;/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula C9H12N5O4
Molecular Weight 254.2227
Charge -1
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/monograph/valganciclovir-hydrochloride.html | http://www.rxlist.com/valcyte-drug/indications-dosage.htm

Ganciclovir is a synthetic acyclic nucleoside analogue of 2'-deoxyguanosine active against cytomegalovirus. Ganciclovir has been shown to be active against cytomegalovirus (CMV) and herpes simplex virus (HSV) in humans. To achieve anti-CMV activity, ganciclovir is phosphorylated first to the monophosphate form by a CMV-encoded (UL97 gene) protein kinase homologue, then to the di- and triphosphate forms by cellular kinases. Ganciclovir triphosphate concentrations may be 100-fold greater in CMV-infected than in uninfected cells, indicating preferential phosphorylation in infected cells. Ganciclovir triphosphate, once formed, persists for days in the CMV-infected cell. Ganciclovir triphosphate is believed to inhibit viral DNA synthesis by (1) competitive inhibition of viral DNA polymerases; and (2) incorporation into viral DNA, resulting in eventual termination of viral DNA elongation. Ganciclovir is indicated for the treatment of CMV retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS) and for the treatment of acute herpetic keratitis.

Originator

Curator's Comment: The first synthesis of ganciclovir was reported by Julien Verheyden and John Martin at Syntex Research in California in 1980 and is marketed as sodium salt (Ganciclovir sodium) under the trade names Cytovene and Cymevene.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P08546
Gene ID: NA
Gene Symbol: UL54
Target Organism: Human cytomegalovirus (strain AD169) (HHV-5) (Human herpesvirus 5)
0.08 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZIRGAN

Approved Use

ZIRGAN is a topical ophthalmic antiviral that is indicated for the treatment of acute herpetic keratitis (dendritic ulcers).

Launch Date

8.1362878E11
Primary
CYTOVENE

Approved Use

CYTOVENE-IV is indicated for the treatment of CMV retinitis in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS). CYTOVENE-IV is also indicated for the prevention of CMV disease in transplant recipients at risk for CMV disease.

Launch Date

7.8805441E11
Primary
VALCYTE

Approved Use

VALCYTE is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS)

Launch Date

9.8573759E11
Primary
VALCYTE

Approved Use

VALCYTE is indicated for the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk

Launch Date

9.8573759E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4.8 mg/L
1 g 3 times / day multiple, oral
dose: 1 g
route of administration: Oral
experiment type: MULTIPLE
co-administered:
GANCICLOVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
13.3 μg/mL
5 mg/kg single, intravenous
dose: 5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GANCICLOVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
35.4 mg × h/L
1 g 3 times / day multiple, oral
dose: 1 g
route of administration: Oral
experiment type: MULTIPLE
co-administered:
GANCICLOVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
53.8 μg × h/mL
5 mg/kg single, intravenous
dose: 5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GANCICLOVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.2 h
5 mg/kg single, intravenous
dose: 5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GANCICLOVIR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1000 mg 6 times / day multiple, oral
Highest studied dose
Dose: 1000 mg, 6 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 6 times / day
Sources:
unhealthy, 37.4
n = 19
Health Status: unhealthy
Condition: AIDS
Age Group: 37.4
Population Size: 19
Sources:
2000 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 3 times / day
Sources:
unhealthy, 38.6
n = 50
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 38.6
Population Size: 50
Sources:
Other AEs: Neutropenia, Thrombocytopenia...
Other AEs:
Neutropenia (18%)
Thrombocytopenia (4%)
Anemia (severe, 4%)
Renal impairment (4%)
Sources:
50 mg/kg 3 times / day multiple, oral
Highest studied dose
Dose: 50 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg/kg, 3 times / day
Sources:
unhealthy, 7.4 years (range: 0.5-16.9 years)
n = 36
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 7.4 years (range: 0.5-16.9 years)
Population Size: 36
Sources:
Other AEs: Neutropenia...
Other AEs:
Neutropenia (22%)
Sources:
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Other AEs: Fever, Infection...
Other AEs:
Fever (48%)
Infection (13%)
Chills (10%)
Sepsis (15%)
Diarrhea (44%)
Anorexia (14%)
Vomiting (13%)
Leukopenia (41%)
Anemia (25%)
Thrombocytopenia (6%)
Neuropathy (9%)
Sweating (12%)
Pruritus (5%)
Catheter infection (9%)
Catheter sepsis (8%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Neutropenia 18%
2000 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 3 times / day
Sources:
unhealthy, 38.6
n = 50
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 38.6
Population Size: 50
Sources:
Renal impairment 4%
2000 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 3 times / day
Sources:
unhealthy, 38.6
n = 50
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 38.6
Population Size: 50
Sources:
Thrombocytopenia 4%
2000 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 3 times / day
Sources:
unhealthy, 38.6
n = 50
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 38.6
Population Size: 50
Sources:
Anemia severe, 4%
2000 mg 3 times / day multiple, oral
Highest studied dose
Dose: 2000 mg, 3 times / day
Route: oral
Route: multiple
Dose: 2000 mg, 3 times / day
Sources:
unhealthy, 38.6
n = 50
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 38.6
Population Size: 50
Sources:
Neutropenia 22%
50 mg/kg 3 times / day multiple, oral
Highest studied dose
Dose: 50 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 50 mg/kg, 3 times / day
Sources:
unhealthy, 7.4 years (range: 0.5-16.9 years)
n = 36
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: 7.4 years (range: 0.5-16.9 years)
Population Size: 36
Sources:
Chills 10%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Sweating 12%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Infection 13%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Vomiting 13%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Anorexia 14%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Sepsis 15%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Anemia 25%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Leukopenia 41%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Diarrhea 44%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Fever 48%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Pruritus 5%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Thrombocytopenia 6%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Catheter sepsis 8%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Catheter infection 9%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
Neuropathy 9%
5 mg/kg 1 times / day multiple, intravenous
Recommended
Dose: 5 mg/kg, 1 times / day
Route: intravenous
Route: multiple
Dose: 5 mg/kg, 1 times / day
Sources:
unhealthy, adult
n = 179
Health Status: unhealthy
Condition: CMV retinitis in HIV infection
Age Group: adult
Sex: M+F
Population Size: 179
Sources:
PubMed

PubMed

TitleDatePubMed
Design and SAR study of a novel class of nucleotide analogues as potent anti-HCMV agents.
1999 Apr-May
Structure-activity relationships of L-dioxolane uracil nucleosides as anti-Epstein Barr virus agents.
1999 Jun 17
The cyclohexene ring system as a furanose mimic: synthesis and antiviral activity of both enantiomers of cyclohexenylguanine.
2000 Feb 24
A novel peptide aldehyde with activity against human cytomegalovirus in two different in vivo models.
2000 Jan
Synthesis and antiviral evaluation of halogenated beta-D- and -L-erythrofuranosylbenzimidazoles.
2000 Jun 15
Thienothiadiazine 2,2-dioxide acyclonucleosides: synthesis and antiviral activity.
2000 May
Prophylaxis against herpesvirus infections in transplant recipients.
2001
Pharmacokinetics of the ganciclovir implant in the silicone-filled eye.
2001
Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality.
2001 Apr 1
Adenoviral-mediated gene therapy for thyroid carcinoma using thymidine kinase controlled by thyroglobulin promoter demonstrates high specificity and low toxicity.
2001 Feb
Conditional abatement of tissue fibrosis using nucleoside analogs to selectively corrupt DNA replication in transgenic fibroblasts.
2001 Feb
Preemptive ganciclovir for CMV viremia in liver transplantation.
2001 Feb-Mar
Is preemptive therapy for CMV infection following liver transplantation superior to symptom-triggered treatment?
2001 Feb-Mar
Cytomegalovirus infection-enhanced chronic rejection in the rat is prevented by antiviral prophylaxis.
2001 Feb-Mar
Ganciclovir prophylaxis for cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone.
2001 Feb-Mar
Rat glioma cell death induced by cationic liposome-mediated transfer of the herpes simplex virus thymidine kinase gene followed by ganciclovir treatment.
2001 Jan
Targeting the replication of adenovirus to p53-defective thyroid carcinoma with a p53-regulated Cre/loxP system.
2001 Jan
[Gene therapy for colorectal cancer].
2001 Jan
[Perspectives on postgenome medicine: Gene therapy for brain tumors].
2001 Jan
In vitro effects of antiviral agents on human keratocytes.
2001 Jan
Management of complications associated with totally implantable ports in patients with AIDS.
2001 Jan
Isolation and analysis of an aciclovir-resistant murine cytomegalovirus mutant.
2001 Jan
Gene therapy for hepatocellular carcinoma based on tumour-selective suicide gene expression using the alpha-fetoprotein (AFP) enhancer and a housekeeping gene promoter.
2001 Jan
Retinal detachment risk in cytomegalovirus retinitis related to the acquired immunodeficiency syndrome.
2001 Jan
Ganciclovir-loaded albumin nanoparticles: characterization and in vitro release properties.
2001 Jan
Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene.
2001 Jan 1
Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation.
2001 Jan 15
Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
2001 Jan 15
Human beta-herpesvirus interactions in solid organ transplant recipients.
2001 Jan 15
Fatal primary infection due to human herpesvirus 6 variant A in a renal transplant recipient.
2001 Jan 27
Toxic megacolon: remember cytomegalovirus.
2001 Mar
The real danger of lamivudine-resistant hepatitis B virus infection in the immunocompromised host.
2001 Mar
Frosted branch angiitis in a child with HIV infection.
2001 Mar
New developments in the management of cytomegalovirus infection and disease after renal transplantation.
2001 Mar
Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation.
2001 Mar-Apr
Top 1% of Inpatients Administered Antimicrobial Agents Comprising 50% of Expenditures: A Descriptive Study and Opportunities for Stewardship Intervention.
2017 Mar
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Ganciclovir can be used as ophthalmic gel 1 drop in the affected eye 5 times per day in patients with acute herpetic keratitis.
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Curator's Comment: The median concentration of ganciclovir that inhibits CMV replication (IC50) in vitro (laboratory strains or clinical isolates) has ranged from 0.02 to 3.48 ug/mL.
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 16 16:17:59 UTC 2022
Edited
by admin
on Fri Dec 16 16:17:59 UTC 2022
Record UNII
02L083W284
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GANCICLOVIR SODIUM
MART.   ORANGE BOOK   USAN   WHO-DD  
USAN  
Official Name English
GANCICLOVIR SODIUM [MART.]
Common Name English
Ganciclovir sodium [WHO-DD]
Common Name English
GANCICLOVIR (AS SODIUM) [VANDF]
Common Name English
GANCICLOVIR SODIUM SALT [MI]
Common Name English
RS-21592 SODIUM
Code English
CYTOVENE IV
Brand Name English
9-[[2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine, monosodium salt
Common Name English
CYTOVENE
Brand Name English
GANCICLOVIR SODIUM SALT
MI  
Common Name English
GANCICLOVIR SODIUM [ORANGE BOOK]
Common Name English
6H-PURIN-6-ONE, 2-AMINO-1,9-DIHYDRO-9-((2-HYDROXY-1-(HYDROXYMETHYL)ETHOXY)METHYL)-, MONOSODIUM SALT
Common Name English
GANCICLOVIR SODIUM [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1556
Created by admin on Fri Dec 16 16:17:59 UTC 2022 , Edited by admin on Fri Dec 16 16:17:59 UTC 2022
NCI_THESAURUS C29575
Created by admin on Fri Dec 16 16:17:59 UTC 2022 , Edited by admin on Fri Dec 16 16:17:59 UTC 2022
NCI_THESAURUS C281
Created by admin on Fri Dec 16 16:17:59 UTC 2022 , Edited by admin on Fri Dec 16 16:17:59 UTC 2022
FDA ORPHAN DRUG 7985
Created by admin on Fri Dec 16 16:17:59 UTC 2022 , Edited by admin on Fri Dec 16 16:17:59 UTC 2022
Code System Code Type Description
EVMPD
SUB02312MIG
Created by admin on Fri Dec 16 16:17:59 UTC 2022 , Edited by admin on Fri Dec 16 16:17:59 UTC 2022
PRIMARY
WIKIPEDIA
Ganciclovir sodium
Created by admin on Fri Dec 16 16:17:59 UTC 2022 , Edited by admin on Fri Dec 16 16:17:59 UTC 2022
PRIMARY
EPA CompTox
DTXSID20883175
Created by admin on Fri Dec 16 16:17:59 UTC 2022 , Edited by admin on Fri Dec 16 16:17:59 UTC 2022
PRIMARY
RXCUI
82131
Created by admin on Fri Dec 16 16:17:59 UTC 2022 , Edited by admin on Fri Dec 16 16:17:59 UTC 2022
PRIMARY RxNorm
USAN
Z-46
Created by admin on Fri Dec 16 16:17:59 UTC 2022 , Edited by admin on Fri Dec 16 16:17:59 UTC 2022
PRIMARY
ChEMBL
CHEMBL182
Created by admin on Fri Dec 16 16:17:59 UTC 2022 , Edited by admin on Fri Dec 16 16:17:59 UTC 2022
PRIMARY
DRUG BANK
DBSALT000309
Created by admin on Fri Dec 16 16:17:59 UTC 2022 , Edited by admin on Fri Dec 16 16:17:59 UTC 2022
PRIMARY
DAILYMED
02L083W284
Created by admin on Fri Dec 16 16:17:59 UTC 2022 , Edited by admin on Fri Dec 16 16:17:59 UTC 2022
PRIMARY
PUBCHEM
23700083
Created by admin on Fri Dec 16 16:17:59 UTC 2022 , Edited by admin on Fri Dec 16 16:17:59 UTC 2022
PRIMARY
CAS
107910-75-8
Created by admin on Fri Dec 16 16:17:59 UTC 2022 , Edited by admin on Fri Dec 16 16:17:59 UTC 2022
PRIMARY
FDA UNII
02L083W284
Created by admin on Fri Dec 16 16:17:59 UTC 2022 , Edited by admin on Fri Dec 16 16:17:59 UTC 2022
PRIMARY
NCI_THESAURUS
C1588
Created by admin on Fri Dec 16 16:17:59 UTC 2022 , Edited by admin on Fri Dec 16 16:17:59 UTC 2022
PRIMARY
MERCK INDEX
M5663
Created by admin on Fri Dec 16 16:17:59 UTC 2022 , Edited by admin on Fri Dec 16 16:17:59 UTC 2022
PRIMARY Merck Index
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY